CombiMatrix to Provide SARS Microarrays at No Cost to Key Research Centers; Toronto's Mt. Sinai Hospital First Group to Receive CombiMatrix SARS Microarrays.Business Editors/Health/Medical Writers BIOWIRE2K NEWPORT BEACH, Calif.--(BUSINESS WIRE)--April 23, 2003 Acacia Research Corporation (Nasdaq:ACTG ACTG Acting ACTG AIDS Clinical Trial Group ACTG Actuating/Actuator )(Nasdaq:CBMX) today announced that CombiMatrix will make its new SARS (Severe Acute Respiratory Syndrome Severe Acute Respiratory Syndrome (SARS) Definition Severe acute respiratory syndrome (SARS) is the first emergent and highly transmissible viral disease to appear during the twenty-first century. ) microarrays available to key government and academic researchers. "Due to the public health and economic implications of SARS, we have decided to offer a limited number of SARS microarrays at no cost to key research centers," said Dr. Amit Kumar, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CombiMatrix. "I am amazed at how quickly CombiMatrix was able to prepare a custom microarray after the sequence was published," stated Dr. Chi Yip Ho, Director of the Microarray Laboratory of the Samuel Lunenfeld Research Institute The Samuel Lunenfeld Research Institute of Mount Sinai Hospital (Toronto), Ontario, Canada was established in 1985 by an endowment from the Lunenfeld and Kunin families. It comprises 31 principal investigators, has a budget of C$90 million (2005/6), has 225 trainees and over 550 at the Mt. Sinai Hospital in Toronto. "It is heartening heart·en tr.v. heart·ened, heart·en·ing, heart·ens To give strength, courage, or hope to; encourage. See Synonyms at encourage. Adj. 1. to see the cooperation between commercial and academic centers on SARS. Mt. Sinai is one of the key centers treating cases of SARS in Toronto. I look forward to working with CombiMatrix and other researchers to enable a better understanding of the virus that will lead to new diagnostics and therapeutics." "The SARS Genome was published on April 14, 2003, and we were contacted by Dr. Ho the following day requesting information about our customizable microarray platform," Kumar said. "Dr. Ho's request prompted us to fabricate the first SARS microarrays for research use. These microarrays can be used in both basic and clinical research to support studies to understand the mechanism of infection and to potentially aid in the development of diagnostic tests, as well as therapeutics, against this disease." The CombiMatrix technology enables rapid content redesign and overnight synthesis of custom microarrays. The microarrays can also contain probes for genes in several host pathways. The CombiMatrix open platform allows researchers to use customized microarrays for their specific and immediate needs. About Acacia Research Corporation Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group. The Acacia Technologies group licenses its DMT See DSL. and V-Chip technologies to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents. The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications, from DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. synthesis/diagnostics to immunochemical im·mu·no·chem·is·try n. The chemistry of immunologic phenomena, as of antigen-antibody reactions. im detection. Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com. Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. , recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion